Kymera Therapeutics, INC Form 4 insider transactions

Terence Rooney, Chief Medical Officer of Kymera Therapeutics, Inc., reported multiple transactions in common stock on July 27, 2026.

Kymera Therapeutics CEO Nello Mainolfi executed trades involving company stock and stock options under a pre-arranged Rule 10b5-1 trading plan.

Kymera Therapeutics' Chief Financial Officer, Bruce N. Jacobs, reported transactions involving the sale of common stock and the acquisition of stock options on June 30, 2026, executed under a Rule 10b5-1 trading plan.

Noah Goodman, Chief Business Officer at Kymera Therapeutics, Inc., reported transactions involving common stock, including purchases made under a Rule 10b5-1 trading plan.

Nello Mainolfi, CEO of Kymera Therapeutics, executed a series of stock transactions on July 1, 2026, under a pre-arranged Rule 10b5-1 trading plan.

Bruce Booth, a Director at Kymera Therapeutics, has filed an amended Form 4 detailing adjustments to his beneficial ownership of common stock, primarily related to sales executed under a Rule 10b5-1 trading plan.

Kymera Therapeutics Director Bruce Booth reported the sale of company stock totaling over 27,000 shares through a Rule 10b5-1 trading plan.

Kymera Therapeutics Director Bruce Booth reported the sale of common stock valued at over $2.5 million through a pre-arranged 10b5-1 trading plan.

BVF Partners L.P. and affiliated entities have reported substantial changes in their beneficial ownership of Kymera Therapeutics, Inc. (KYMR) common stock.

Kymera Therapeutics Director Bruce Booth reported the sale of common stock valued at over $350 million through a Rule 10b5-1 trading plan.

Bruce Booth, a Director at Kymera Therapeutics, Inc., reported the sale of a significant number of common shares between June 23 and June 25, 2026, executed under a Rule 10b5-1 trading plan.

BVF Partners L.P. and affiliated entities have filed a Form 4 detailing changes in their beneficial ownership of Kymera Therapeutics, Inc. (KYMR) stock, including the acquisition and disposition of common stock and derivative securities.

Kymera Therapeutics Director Bruce Booth acquired stock options for 6,068 shares of common stock.

Kymera Therapeutics Director Gorjan Hrustanovic acquired stock options for 6,068 shares of common stock.

Kymera Therapeutics Director Jeffrey W. Albers acquired 6,068 stock options with an exercise price of $99.87, as detailed in a Form 4 filing.

Noah Goodman, Chief Business Officer at Kymera Therapeutics, executed a series of stock transactions on June 25, 2026, under a pre-arranged trading plan.

Kymera Therapeutics Director Elena Ridloff acquired stock options for 6,068 shares of common stock.

Kymera Therapeutics Director Victor Sandor acquired stock options for 6,068 shares of common stock on June 24, 2026.

Kymera Therapeutics Director John Maraganore reported the acquisition of stock options for 6,068 shares.

Pamela Esposito, a Director at Kymera Therapeutics, Inc., reported the acquisition of stock options.

Baker Bros. Advisors LP, a significant holder and director representative, reported the grant of 6,068 non-qualified stock options to Felix J. Baker.

Kymera Therapeutics' Chief Financial Officer, Bruce N. Jacobs, acquired 12,653 shares of common stock on June 2, 2026, at a price of $2.08 per share.

Kymera Therapeutics Chief Operating Officer Jeremy G. Chadwick sold 17,184 shares of common stock to cover tax obligations and pursuant to a Rule 10b5-1 trading plan.

Kymera Therapeutics' Chief Financial Officer, Bruce N. Jacobs, acquired 15,000 shares of common stock.

Kymera Therapeutics Director Elena Ridloff reported transactions involving the purchase and sale of company stock, executed under a pre-arranged trading plan.

Nello Mainolfi, CEO of Kymera Therapeutics, reports transactions involving the acquisition of stock options and the sale of common stock under a Rule 10b5-1 trading plan.

Director Bruce Booth exercised stock options and sold shares of Kymera Therapeutics under a pre-arranged 10b5-1 trading plan.

Kymera Therapeutics COO Jeremy G. Chadwick exercised stock options and sold shares under a pre-established Rule 10b5-1 trading plan.

Chief Business Officer Noah Goodman sold 1,347 shares of Kymera Therapeutics common stock at $90 per share.

Kymera Therapeutics Chief Operating Officer Jeremy G. Chadwick exercised stock options and sold shares under a Rule 10b5-1 trading plan.